Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Growth Rate of the Primary Biliary Cholangitis Market Shape Industry Trends by 2034?

The market size for primary biliary cholangitis has significantly expanded in the past few years. The growth is projected to continue from $0.98 billion in 2024 to $1.09 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. This expansion during the historic period is credited to enhanced disease recognition, escalated worldwide medical care spending, strategic alliances in the medical field, emphasis on patient representation, and governmental efforts towards liver health.

In the coming years, it is predicted that the primary biliary cholangitis market will experience robust growth, expanding to $1.6 billion in 2029 with a compound annual growth rate (CAGR) of 9.9%. This growth during the predicted period is likely due to several factors such as the expansion of biomarker research, worldwide initiatives in managing rare diseases, increased partnerships in clinical trials, patient-oriented healthcare methodologies, and an escalating need for liver transplants. Significant trends for the forecast period entail advancement in biomarker research, an increased focus on non-invasive diagnostic methods, research emphasis on immunomodulatory therapies, the incorporation of artificial intelligence (ai), patient-reported results in clinical trials, the application of telemedicine for patient management, a focus on combination therapies, and upcoming therapies targeting fibrosis.

What Major Innovations Are Driving the Accelerated Growth of the Primary Biliary Cholangitis Market?

The primary biliary cholangitis market is poised for growth, spurred on by the rising prevalence of smoking. This act entails the inhalation and exhalation of smoke from burning tobacco or other substances. It’s recognized that smoking is a risk factor for liver diseases, inclusive of PBC, and a rise in smoking will result in a greater number of people seeking healthcare for liver-related conditions. For example, government agency, Statistics Canada, reported that cigarette production in July 2023 witnessed an increase by 2.2% from June 2023, and there was a 2.6% uptick in cigarette sales in the same month, reaching 1.4 billion units. Therefore, the primary biliary cholangitis market is set to benefit from increasing smoking rates.

Primary Biliary Cholangitis Market Driver: Increase in Liver Cancer Cases Boosts Growth in Primary Biliary Cholangitis Market

Get Your Free Sample of the Global Primary Biliary Cholangitis Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Who Are the Key Market Players Influencing the Growth of the Primary Biliary Cholangitis Industry?

Major companies operating in the primary biliary cholangitis market report are:

• Pfizer Inc._x000D_

• F. Hoffmann-La Roche Ltd._x000D_

• Merck And Co. Inc._x000D_

• Novartis AG_x000D_

• Bristol-Myers Squibb Company_x000D_

What Key Market Trends Are Shaping the Future of the Primary Biliary Cholangitis Industry?

Organizations operating within the primary biliary cholangitis market are aiming to carve out an exclusive niche for themselves by creating specialized and novel treatments. These include a mix of obeticholic acid (OCA) and bezafibrates, designated as orphan drugs, aimed specifically at tackling primary biliary cholangitis (PBC). The objective is to offer a comprehensive and superior method of managing PBC, increasing the potential to enhance the quality of life for those suffering from this uncommon disease. For instance, Intercept Pharmaceuticals, Inc., a biopharmaceutical entity from the US, was granted the status of an orphan drug by the FDA in May 2023. This was for the combined use of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a possible means of treating primary biliary cholangitis (PBC), a degenerative liver disease. The US has approved the use of obeticholic acid (known in the market as Ocaliva) for PBC treatment.

Get Instant Access to the Global Primary Biliary Cholangitis Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

What Are the Main Segments of the Primary Biliary Cholangitis Market, and How Are They Evolving?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

Which Regions Are Emerging as Leaders in the Primary Biliary Cholangitis Market?

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Features of the Primary Biliary Cholangitis Market?

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.

Browse Through More Similar Reports By The Business Research Company:

Neuropathic Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Pituitary Dwarf Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

Myelodysplastic Syndrome Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: